LOS ANGELES, Oct. 21, 2019 /PRNewswire/ -- B. Riley FBR,
Inc., a full-service investment bank and a B. Riley Financial
company (NASDAQ: RILY) ("B. Riley"), today announced it will host a
biotech investor event to discuss emerging trends in non-alcoholic
steatohepatitis (NASH) on Thursday, October
24, 2019, in San Francisco.
This invitation-only NASH Symposium will gather institutional
investors and senior management teams across the healthcare
industry to discuss the latest developments and treatments for
non-alcoholic fatty liver disease (NAFLD)—one of the most common
liver diseases in the world.
NASH industry experts will have an opportunity to delve into the
controversies related to scientific mechanisms, preclinical and
clinical development programs, regulatory endpoints, and the market
potential of emerging treatment options for "true" NASH
non-cirrhotic and cirrhotic patients.
"Biopharma industry investments in NASH have significantly
increased over the last three years given the enormous burden to
the healthcare system, the volume of affected patients, and the
chronic nature of the disease," said Mayank
Mamtani, Senior Biotech Research Analyst, B. Riley FBR.
"NAFLD is expected to become the leading cause of liver
transplantation by 2020, with approximately 60-80 million people,
or 20-25 percent of the U.S. adult population impacted. There is
currently no FDA-approved treatment option for this costly, broad
spectrum disease."
The NASH Symposium will feature facilitated company and investor
discussions with key opinion leader, Dr. Stephen Harrison, an internationally known
expert in hepatitis C and NAFLD. Company participants currently
include:
- Altimmune (ALT)
- Cirius Pharmaceuticals (private)
- Durect Corporation (DRRX)
- Genfit SA (GNFT)
- Gilead Sciences (GILD)
- INmune Bio (INMB)
- Lipocine (LPCN)
- NGM Biopharmaceuticals (NGM)
- Sagimet Biosciences (private)
- Terns Pharmaceuticals (private)
The event is by invitation only. Interested participants may
contact their B. Riley FBR representative for more information. A
complete schedule will be provided upon registration.
About B. Riley FBR, Inc.
B. Riley FBR is a
full-service investment bank and subsidiary of B. Riley Financial,
which provides corporate finance, research and sales and trading to
corporate, institutional and high-net-worth individual clients.
Investment banking services include initial, secondary and
follow-on offerings, institutional private placements, merger and
acquisitions advisory services, and corporate restructuring. The
firm is nationally recognized for its highly ranked proprietary
equity research. For more information, visit www.brileyfbr.com.
About B. Riley Financial, Inc. (NASDAQ:RILY)
B. Riley
Financial provides collaborative financial services tailored to fit
the capital raising and business advisory needs of public and
private companies and high-net-worth individuals. B. Riley operates
through several wholly-owned subsidiaries which offer complementary
end-to-end capabilities spanning investment banking and
institutional brokerage, private wealth and investment management,
corporate advisory, restructuring, due diligence, forensic
accounting and litigation support, appraisal and valuation, and
auction and liquidation services. Certain registered affiliates of
B. Riley originate and underwrite senior secured loans for
asset-rich companies. The Company also makes proprietary
investments in companies and assets with attractive return
profiles. For more information, visit www.brileyfin.com.
Media Contact
Jo Anne McCusker
B. Riley Financial
jmccusker@brileyfin.com
(646) 885-5425
View original content to download
multimedia:http://www.prnewswire.com/news-releases/b-riley-fbr-to-host-nash-symposium-in-san-francisco-on-october-24-2019-300942077.html
SOURCE B. Riley FBR, a B. Riley Financial company